Thelansis

  Pseudoxanthoma elasticum (PXE) is an inherited metabolic disorder due to ABCC6 gene mutations. It is characterized by progressive calcification and fragmentation of elastic fibers in the skin, retina, and arterial wall. Despite calcium accumulation in the arteries of PXE patients, functional consequences remain unknown.   Epidemiology- According to the literature review conducted by Thelansis, the prevalence of PXE estimated to be 1 in 50,000 would imply that there are ~8,000–10,000 PXE patients in the United States. With the same global prevalence, there could be as many as 160,000 to 200,000 patients affected with PXE worldwide.   The competitive landscape of Pseudoxanthoma elasticum (PXE) includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary. KOLs insights of Pseudoxanthoma elasticum (PXE) across 8 MM market fro...